ADZYNMA Market Report 2026

ADZYNMA Market Overview

• The ADZYNMA market growth in the historic period has been driven by limited treatment availability for cTTP, high mortality rates in untreated patients • Market expansion is supported by growth in rare disease awareness programs, improved affordability of targeted therapies • Growth Driver: Impact Of Rising Autoimmune Disorders On The ADZYNMA Market Growth • Market Trend: Advancements In Biologic Drug Development • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under ADZYNMA Market?

Adzynma is a medication used to treat congenital thrombotic thrombocytopenic purpura (cTTP), a genetic disorder brought on by mutations (alterations) in the ADAMTS13 gene, in both children and adults. It is developed to provide a cost-effective alternative with similar efficacy and safety, improving patient access to life-saving treatments. The main indication types of ADZYNMA are autoimmune diseases, inflammatory diseases, and others. Autoimmune diseases occur when the immune system mistakenly attacks the body's own tissues, leading to inflammation and damage in various organs or systems. The distribution channels are hospitals and clinics and retail and specialty pharmacies, and the end users include adult patients and pediatric patients.

What Is The ADZYNMA Market Growth Forecast?

The growth in the forecast period can be attributed to growth in rare disease awareness programs, improved affordability of targeted therapies, expansion of specialty treatment centers, rising genetic screening adoption, increased public healthcare funding. Major trends in the forecast period include growing focus on rare genetic blood disorders, increased access to cost-effective biologic therapies, expansion of pediatric and adult treatment coverage, rising importance of early genetic diagnosis, improved availability of targeted therapies.

Global ADZYNMA Market Segmentation

1) By Indication: Autoimmune Diseases, Inflammatory Diseases, Other Conditions 2) By Distribution Channel: Hospitals And Clinics, Retail And Specialty Pharmacies 3) By End-User: Adult Patients, Pediatric Patients

What Is The Driver Of The ADZYNMA Market?

The growing prevalence of autoimmune disorders is expected to propel the growth of the ADZYNMA market going forward. Autoimmune disorders are conditions in which the body's immune system mistakenly attacks its own tissues, leading to chronic inflammation and damage to various organs. The increasing prevalence of these disorders can be attributed to various factors, including genetic predispositions, environmental triggers, and lifestyle changes. ADZYNMA is a therapeutic agent used to modulate immune responses in autoimmune disorders, targeting pathways to reduce inflammation and prevent tissue damage. For instance, in July 2025, according to the data from Public Health Scotland, a Scotland-based national organization, in 2024, newly diagnosed patients with multiple sclerosis (MS) were, 470 and added to the SMSR. The proportion of newly diagnosed patients receiving contact from a MS specialist nurse within 10 working days of diagnosis increased from 88.3% in 2023 to 93.3% in 2024. Therefore, the growing prevalence of autoimmune disorders drives the ADZYNMA industry.

Key Players In The Global ADZYNMA Market

Major companies operating in the adzynma market are Takeda Pharmaceutical Company Limited

Global ADZYNMA Market Trends and Insights

Major companies operating in the ADZYNMA market are focusing on advancements in biologic drug development to gain a competitive edge in the industry. These include innovations such as monoclonal antibodies, fusion proteins, and recombinant biologics, which improve treatment precision and reduce side effects compared to traditional therapies. For instance, in November 2023, Takeda, a Japan-based biopharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) approved ADZYNMA (ADAMTS13, recombinant-krhn) for both prophylactic and on-demand treatment of adult and pediatric patients with congenital thrombotic thrombocytopenic purpura (cTTP). As the first and only FDA-approved recombinant ADAMTS13 (rADAMTS13) protein, ADZYNMA fulfills a critical medical need by replacing the deficient ADAMTS13 enzyme in individuals with cTTP.

What Are Latest Mergers And Acquisitions In The ADZYNMA Market?

In February 2024, Takeda, a Japan-based biopharmaceutical company partnered with Protagonist Therapeutics to develop and market rusfertide. The partnership capitalizes on Takeda's expertise in rare hematology, exemplified by the recent FDA approval of ADZYNMA for treating congenital thrombotic thrombocytopenic purpura. Protagonist Therapeutics is a US-based biopharmaceutical company specializing in peptide-based therapeutics.

Regional Insights

North America was the largest region in the ADZYNMA market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

What Defines the ADZYNMA Market?

The ADZYNMA market consists of sales of biologic therapies for autoimmune and inflammatory diseases. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the ADZYNMA Market Report 2026?

The adzynma market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the adzynma industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.